PT  - JOURNAL ARTICLE
AU  - Alyson Craigie
AU  - Reuben McGregor
AU  - Alana Whitcombe
AU  - Lauren Carlton
AU  - David Harte
AU  - Michelle Sutherland
AU  - Matthew Parry
AU  - Erasmus Smit
AU  - Gary McAuliffe
AU  - James Ussher
AU  - Nicole Moreland
AU  - Susan Jack
AU  - Arlo Upton
TI  - SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020
AID  - 10.1101/2020.10.20.20215616
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.20.20215616
4099  - http://medrxiv.org/content/early/2020/10/23/2020.10.20.20215616.short
4100  - http://medrxiv.org/content/early/2020/10/23/2020.10.20.20215616.full
AB  - Background During New Zealand’s first outbreak in early 2020 the Southern Region had the highest per capita SARS-CoV-2 infection rate. PCR testing was initially limited by a narrow case definition and limited laboratory capacity, so cases may have been missed.Objectives To evaluate the Abbott® SARS-CoV-2 IgG nucleocapsid assay, alongside spike-based assays, and to determine the frequency of antibodies among PCR-confirmed and probable cases, contacts, and higher risk individuals in the Southern Region of NZ.Study design Pre-pandemic sera (n=300) were used to establish assay specificity and sera from PCR-confirmed SARS-CoV-2 patients (n=78) to establish sensitivity. For prevalence analysis, all samples (n=1214) were tested on the Abbott assay, and all PCR-confirmed cases (n=78), probable cases (n=9), and higher risk individuals with grey-zone (n=14) or positive results (n=11) were tested on four additional SARS-CoV-2 serological assays.Results The median time from infection onset to serum collection for PCR-confirmed cases was 14 weeks (range 11-17 weeks). The Abbott assay demonstrated a specificity of 99.7% (95% CI, 98.2%-99.99%) and a sensitivity of 76.9% (95% CI, 66.0%-85.7%). Spike-based assays demonstrated superior sensitivity ranging 89.7-94.9%. Nine previously undiagnosed sero-positive individuals were identified, and all had epidemiological risk factors.Conclusions Spike-based assays demonstrated higher sensitivity than the Abbott IgG assay, likely due to temporal differences in antibody persistence. No unexpected SARS-CoV-2 infections were found in the Southern region of NZ, supporting the elimination status of the country at the time this study was conducted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:New Zealand Health and Disability Ethics Committee (ethics number: 20/NTB/101)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, AU, upon reasonable request.